研究发现肿瘤微环境导致获得性耐药新机制

2016-01-22 黄辛中国科学报

中科院上海健康所研究发现肿瘤微环境导致获得性耐药新机制中科院上海生科院上海交大医学院健康科学研究所孙宇研究组揭示了Wnt信号通路在肿瘤耐药性形成过程中的核心地位和分子机制，颠覆了人们对于SFRP2分子在很多癌型中对于Wnt通路拮抗作用的传统认识。相关成果近日在线发表于《癌基因》。研究人员以全基因组表达谱分析发现，一种与Wnt信号通路调控有关的可溶因子SFRP2在经过基因毒试剂处理

中科院上海健康所研究发现肿瘤微环境导致获得性耐药新机制

中科院上海生科院上海交大医学院健康科学研究所孙宇研究组揭示了Wnt信号通路在肿瘤耐药性形成过程中的核心地位和分子机制，颠覆了人们对于SFRP2分子在很多癌型中对于Wnt通路拮抗作用的传统认识。相关成果近日在线发表于《癌基因》。

研究人员以全基因组表达谱分析发现，一种与Wnt信号通路调控有关的可溶因子SFRP2在经过基因毒试剂处理过的前列腺基质细胞PSC27中被高度上调。癌细胞的增殖率、迁移率、侵袭性和异质性，均在广谱PSC27-RAD胞外液作用下大幅提高，而一旦SFRP2被清除，以上活性则显著减弱。WNT16B上调前列腺癌细胞对化疗试剂的耐受性，而SFRP2的存在却使其更加明显，暗示前者是该过程的中心分子、后者为辅助因素。利用促使前列腺癌组织内细胞凋亡程度显著上升的WNT16B特异性抗体，模拟临床治疗条件下的生理现实，针对负荷移植瘤的免疫缺陷型小鼠进行化疗和抗体给药，发现化疗本身使得肿瘤减小近40%，而协同使用免疫疗法可以进一步缩小肿块。

该研究发现微环境中的SFRP2实际是Wnt通路兴奋剂，而特异性抑制WNT16B可促进体内条件下肿瘤细胞凋亡，剥夺肿瘤从损伤性激活的微环境获得耐药性的途径，降低肿瘤对化疗药物的耐药性，为将来转化医学提供了重要借鉴和实验依据。

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言

评论区 (11)

#插入话题

插入图片

[GetPortalCommentsPageByObjectIdResponse(id=2042566, encodeId=5a2f2042566a2, content=<a href='/topic/show?id=999c88014ea' target=_blank style='color:#2F92EE;'>#获得性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88014, encryptionId=999c88014ea, topicName=获得性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d4b7363, createdName=pandamao2010, createdTime=Fri May 20 06:28:00 CST 2016, time=2016-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1753126, encodeId=b4891e5312658, content=<a href='/topic/show?id=6a57e33772b' target=_blank style='color:#2F92EE;'>#研究发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73377, encryptionId=6a57e33772b, topicName=研究发现)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e1736602208, createdName=hanhaisha2020, createdTime=Sat Aug 20 04:28:00 CST 2016, time=2016-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1967062, encodeId=8701196e062a2, content=<a href='/topic/show?id=01068801967' target=_blank style='color:#2F92EE;'>#获得性耐药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88019, encryptionId=01068801967, topicName=获得性耐药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sun Jan 24 15:28:00 CST 2016, time=2016-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=62222, encodeId=55a16222296, content=学习了继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=143, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIuqOuvZLWMJ8yAVHKNPBSKWLKHx7ibIhutJv2OfnTK9MQH5jpicpw5EJTmD0M0q2wOG3CZO9wTxa9A/132, createdBy=75561684788, createdName=yilibaisha, createdTime=Sat Jan 30 14:57:00 CST 2016, time=2016-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=61326, encodeId=8d756132666, content=不错，赞一个, beContent=null, objectType=article, channel=null, level=null, likeNumber=137, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Wed Jan 27 20:10:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=61327, encodeId=619c6132ebe, content=这篇文章有一定深度, beContent=null, objectType=article, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Wed Jan 27 20:10:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=61328, encodeId=9bfe6132839, content=是一篇不错的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Wed Jan 27 20:10:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=61329, encodeId=c0ee613290e, content=非常实用, beContent=null, objectType=article, channel=null, level=null, likeNumber=164, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Wed Jan 27 20:10:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=61330, encodeId=9ad5613301f, content=值得进一步关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=171, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Wed Jan 27 20:10:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=61089, encodeId=bca16108981, content=文章有深度, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Wed Jan 27 18:34:00 CST 2016, time=2016-01-27, status=1, ipAttribution=)]
2016-05-20 pandamao2010

#获得性#

90 0
[GetPortalCommentsPageByObjectIdResponse(id=2042566, encodeId=5a2f2042566a2, content=<a href='/topic/show?id=999c88014ea' target=_blank style='color:#2F92EE;'>#获得性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88014, encryptionId=999c88014ea, topicName=获得性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d4b7363, createdName=pandamao2010, createdTime=Fri May 20 06:28:00 CST 2016, time=2016-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1753126, encodeId=b4891e5312658, content=<a href='/topic/show?id=6a57e33772b' target=_blank style='color:#2F92EE;'>#研究发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73377, encryptionId=6a57e33772b, topicName=研究发现)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e1736602208, createdName=hanhaisha2020, createdTime=Sat Aug 20 04:28:00 CST 2016, time=2016-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1967062, encodeId=8701196e062a2, content=<a href='/topic/show?id=01068801967' target=_blank style='color:#2F92EE;'>#获得性耐药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88019, encryptionId=01068801967, topicName=获得性耐药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sun Jan 24 15:28:00 CST 2016, time=2016-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=62222, encodeId=55a16222296, content=学习了继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=143, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIuqOuvZLWMJ8yAVHKNPBSKWLKHx7ibIhutJv2OfnTK9MQH5jpicpw5EJTmD0M0q2wOG3CZO9wTxa9A/132, createdBy=75561684788, createdName=yilibaisha, createdTime=Sat Jan 30 14:57:00 CST 2016, time=2016-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=61326, encodeId=8d756132666, content=不错，赞一个, beContent=null, objectType=article, channel=null, level=null, likeNumber=137, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Wed Jan 27 20:10:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=61327, encodeId=619c6132ebe, content=这篇文章有一定深度, beContent=null, objectType=article, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Wed Jan 27 20:10:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=61328, encodeId=9bfe6132839, content=是一篇不错的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Wed Jan 27 20:10:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=61329, encodeId=c0ee613290e, content=非常实用, beContent=null, objectType=article, channel=null, level=null, likeNumber=164, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Wed Jan 27 20:10:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=61330, encodeId=9ad5613301f, content=值得进一步关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=171, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Wed Jan 27 20:10:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=61089, encodeId=bca16108981, content=文章有深度, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Wed Jan 27 18:34:00 CST 2016, time=2016-01-27, status=1, ipAttribution=)]
2016-08-20 hanhaisha2020

#研究发现#

70 0
[GetPortalCommentsPageByObjectIdResponse(id=2042566, encodeId=5a2f2042566a2, content=<a href='/topic/show?id=999c88014ea' target=_blank style='color:#2F92EE;'>#获得性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88014, encryptionId=999c88014ea, topicName=获得性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d4b7363, createdName=pandamao2010, createdTime=Fri May 20 06:28:00 CST 2016, time=2016-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1753126, encodeId=b4891e5312658, content=<a href='/topic/show?id=6a57e33772b' target=_blank style='color:#2F92EE;'>#研究发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73377, encryptionId=6a57e33772b, topicName=研究发现)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e1736602208, createdName=hanhaisha2020, createdTime=Sat Aug 20 04:28:00 CST 2016, time=2016-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1967062, encodeId=8701196e062a2, content=<a href='/topic/show?id=01068801967' target=_blank style='color:#2F92EE;'>#获得性耐药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88019, encryptionId=01068801967, topicName=获得性耐药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sun Jan 24 15:28:00 CST 2016, time=2016-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=62222, encodeId=55a16222296, content=学习了继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=143, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIuqOuvZLWMJ8yAVHKNPBSKWLKHx7ibIhutJv2OfnTK9MQH5jpicpw5EJTmD0M0q2wOG3CZO9wTxa9A/132, createdBy=75561684788, createdName=yilibaisha, createdTime=Sat Jan 30 14:57:00 CST 2016, time=2016-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=61326, encodeId=8d756132666, content=不错，赞一个, beContent=null, objectType=article, channel=null, level=null, likeNumber=137, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Wed Jan 27 20:10:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=61327, encodeId=619c6132ebe, content=这篇文章有一定深度, beContent=null, objectType=article, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Wed Jan 27 20:10:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=61328, encodeId=9bfe6132839, content=是一篇不错的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Wed Jan 27 20:10:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=61329, encodeId=c0ee613290e, content=非常实用, beContent=null, objectType=article, channel=null, level=null, likeNumber=164, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Wed Jan 27 20:10:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=61330, encodeId=9ad5613301f, content=值得进一步关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=171, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Wed Jan 27 20:10:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=61089, encodeId=bca16108981, content=文章有深度, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Wed Jan 27 18:34:00 CST 2016, time=2016-01-27, status=1, ipAttribution=)]
2016-01-24 zhaozhouchifen

#获得性耐药#

87 0
[GetPortalCommentsPageByObjectIdResponse(id=2042566, encodeId=5a2f2042566a2, content=<a href='/topic/show?id=999c88014ea' target=_blank style='color:#2F92EE;'>#获得性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88014, encryptionId=999c88014ea, topicName=获得性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d4b7363, createdName=pandamao2010, createdTime=Fri May 20 06:28:00 CST 2016, time=2016-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1753126, encodeId=b4891e5312658, content=<a href='/topic/show?id=6a57e33772b' target=_blank style='color:#2F92EE;'>#研究发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73377, encryptionId=6a57e33772b, topicName=研究发现)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e1736602208, createdName=hanhaisha2020, createdTime=Sat Aug 20 04:28:00 CST 2016, time=2016-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1967062, encodeId=8701196e062a2, content=<a href='/topic/show?id=01068801967' target=_blank style='color:#2F92EE;'>#获得性耐药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88019, encryptionId=01068801967, topicName=获得性耐药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sun Jan 24 15:28:00 CST 2016, time=2016-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=62222, encodeId=55a16222296, content=学习了继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=143, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIuqOuvZLWMJ8yAVHKNPBSKWLKHx7ibIhutJv2OfnTK9MQH5jpicpw5EJTmD0M0q2wOG3CZO9wTxa9A/132, createdBy=75561684788, createdName=yilibaisha, createdTime=Sat Jan 30 14:57:00 CST 2016, time=2016-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=61326, encodeId=8d756132666, content=不错，赞一个, beContent=null, objectType=article, channel=null, level=null, likeNumber=137, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Wed Jan 27 20:10:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=61327, encodeId=619c6132ebe, content=这篇文章有一定深度, beContent=null, objectType=article, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Wed Jan 27 20:10:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=61328, encodeId=9bfe6132839, content=是一篇不错的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Wed Jan 27 20:10:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=61329, encodeId=c0ee613290e, content=非常实用, beContent=null, objectType=article, channel=null, level=null, likeNumber=164, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Wed Jan 27 20:10:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=61330, encodeId=9ad5613301f, content=值得进一步关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=171, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Wed Jan 27 20:10:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=61089, encodeId=bca16108981, content=文章有深度, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Wed Jan 27 18:34:00 CST 2016, time=2016-01-27, status=1, ipAttribution=)]
2016-01-30 yilibaisha

学习了继续关注

143 0
[GetPortalCommentsPageByObjectIdResponse(id=2042566, encodeId=5a2f2042566a2, content=<a href='/topic/show?id=999c88014ea' target=_blank style='color:#2F92EE;'>#获得性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88014, encryptionId=999c88014ea, topicName=获得性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d4b7363, createdName=pandamao2010, createdTime=Fri May 20 06:28:00 CST 2016, time=2016-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1753126, encodeId=b4891e5312658, content=<a href='/topic/show?id=6a57e33772b' target=_blank style='color:#2F92EE;'>#研究发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73377, encryptionId=6a57e33772b, topicName=研究发现)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e1736602208, createdName=hanhaisha2020, createdTime=Sat Aug 20 04:28:00 CST 2016, time=2016-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1967062, encodeId=8701196e062a2, content=<a href='/topic/show?id=01068801967' target=_blank style='color:#2F92EE;'>#获得性耐药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88019, encryptionId=01068801967, topicName=获得性耐药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sun Jan 24 15:28:00 CST 2016, time=2016-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=62222, encodeId=55a16222296, content=学习了继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=143, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIuqOuvZLWMJ8yAVHKNPBSKWLKHx7ibIhutJv2OfnTK9MQH5jpicpw5EJTmD0M0q2wOG3CZO9wTxa9A/132, createdBy=75561684788, createdName=yilibaisha, createdTime=Sat Jan 30 14:57:00 CST 2016, time=2016-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=61326, encodeId=8d756132666, content=不错，赞一个, beContent=null, objectType=article, channel=null, level=null, likeNumber=137, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Wed Jan 27 20:10:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=61327, encodeId=619c6132ebe, content=这篇文章有一定深度, beContent=null, objectType=article, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Wed Jan 27 20:10:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=61328, encodeId=9bfe6132839, content=是一篇不错的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Wed Jan 27 20:10:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=61329, encodeId=c0ee613290e, content=非常实用, beContent=null, objectType=article, channel=null, level=null, likeNumber=164, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Wed Jan 27 20:10:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=61330, encodeId=9ad5613301f, content=值得进一步关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=171, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Wed Jan 27 20:10:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=61089, encodeId=bca16108981, content=文章有深度, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Wed Jan 27 18:34:00 CST 2016, time=2016-01-27, status=1, ipAttribution=)]
2016-01-27 doctording1

不错，赞一个

137 0
[GetPortalCommentsPageByObjectIdResponse(id=2042566, encodeId=5a2f2042566a2, content=<a href='/topic/show?id=999c88014ea' target=_blank style='color:#2F92EE;'>#获得性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88014, encryptionId=999c88014ea, topicName=获得性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d4b7363, createdName=pandamao2010, createdTime=Fri May 20 06:28:00 CST 2016, time=2016-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1753126, encodeId=b4891e5312658, content=<a href='/topic/show?id=6a57e33772b' target=_blank style='color:#2F92EE;'>#研究发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73377, encryptionId=6a57e33772b, topicName=研究发现)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e1736602208, createdName=hanhaisha2020, createdTime=Sat Aug 20 04:28:00 CST 2016, time=2016-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1967062, encodeId=8701196e062a2, content=<a href='/topic/show?id=01068801967' target=_blank style='color:#2F92EE;'>#获得性耐药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88019, encryptionId=01068801967, topicName=获得性耐药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sun Jan 24 15:28:00 CST 2016, time=2016-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=62222, encodeId=55a16222296, content=学习了继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=143, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIuqOuvZLWMJ8yAVHKNPBSKWLKHx7ibIhutJv2OfnTK9MQH5jpicpw5EJTmD0M0q2wOG3CZO9wTxa9A/132, createdBy=75561684788, createdName=yilibaisha, createdTime=Sat Jan 30 14:57:00 CST 2016, time=2016-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=61326, encodeId=8d756132666, content=不错，赞一个, beContent=null, objectType=article, channel=null, level=null, likeNumber=137, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Wed Jan 27 20:10:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=61327, encodeId=619c6132ebe, content=这篇文章有一定深度, beContent=null, objectType=article, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Wed Jan 27 20:10:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=61328, encodeId=9bfe6132839, content=是一篇不错的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Wed Jan 27 20:10:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=61329, encodeId=c0ee613290e, content=非常实用, beContent=null, objectType=article, channel=null, level=null, likeNumber=164, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Wed Jan 27 20:10:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=61330, encodeId=9ad5613301f, content=值得进一步关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=171, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Wed Jan 27 20:10:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=61089, encodeId=bca16108981, content=文章有深度, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Wed Jan 27 18:34:00 CST 2016, time=2016-01-27, status=1, ipAttribution=)]
2016-01-27 doctording1

这篇文章有一定深度

123 0
[GetPortalCommentsPageByObjectIdResponse(id=2042566, encodeId=5a2f2042566a2, content=<a href='/topic/show?id=999c88014ea' target=_blank style='color:#2F92EE;'>#获得性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88014, encryptionId=999c88014ea, topicName=获得性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d4b7363, createdName=pandamao2010, createdTime=Fri May 20 06:28:00 CST 2016, time=2016-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1753126, encodeId=b4891e5312658, content=<a href='/topic/show?id=6a57e33772b' target=_blank style='color:#2F92EE;'>#研究发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73377, encryptionId=6a57e33772b, topicName=研究发现)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e1736602208, createdName=hanhaisha2020, createdTime=Sat Aug 20 04:28:00 CST 2016, time=2016-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1967062, encodeId=8701196e062a2, content=<a href='/topic/show?id=01068801967' target=_blank style='color:#2F92EE;'>#获得性耐药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88019, encryptionId=01068801967, topicName=获得性耐药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sun Jan 24 15:28:00 CST 2016, time=2016-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=62222, encodeId=55a16222296, content=学习了继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=143, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIuqOuvZLWMJ8yAVHKNPBSKWLKHx7ibIhutJv2OfnTK9MQH5jpicpw5EJTmD0M0q2wOG3CZO9wTxa9A/132, createdBy=75561684788, createdName=yilibaisha, createdTime=Sat Jan 30 14:57:00 CST 2016, time=2016-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=61326, encodeId=8d756132666, content=不错，赞一个, beContent=null, objectType=article, channel=null, level=null, likeNumber=137, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Wed Jan 27 20:10:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=61327, encodeId=619c6132ebe, content=这篇文章有一定深度, beContent=null, objectType=article, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Wed Jan 27 20:10:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=61328, encodeId=9bfe6132839, content=是一篇不错的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Wed Jan 27 20:10:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=61329, encodeId=c0ee613290e, content=非常实用, beContent=null, objectType=article, channel=null, level=null, likeNumber=164, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Wed Jan 27 20:10:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=61330, encodeId=9ad5613301f, content=值得进一步关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=171, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Wed Jan 27 20:10:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=61089, encodeId=bca16108981, content=文章有深度, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Wed Jan 27 18:34:00 CST 2016, time=2016-01-27, status=1, ipAttribution=)]
2016-01-27 doctording1

是一篇不错的文章

119 0
[GetPortalCommentsPageByObjectIdResponse(id=2042566, encodeId=5a2f2042566a2, content=<a href='/topic/show?id=999c88014ea' target=_blank style='color:#2F92EE;'>#获得性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88014, encryptionId=999c88014ea, topicName=获得性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d4b7363, createdName=pandamao2010, createdTime=Fri May 20 06:28:00 CST 2016, time=2016-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1753126, encodeId=b4891e5312658, content=<a href='/topic/show?id=6a57e33772b' target=_blank style='color:#2F92EE;'>#研究发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73377, encryptionId=6a57e33772b, topicName=研究发现)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e1736602208, createdName=hanhaisha2020, createdTime=Sat Aug 20 04:28:00 CST 2016, time=2016-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1967062, encodeId=8701196e062a2, content=<a href='/topic/show?id=01068801967' target=_blank style='color:#2F92EE;'>#获得性耐药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88019, encryptionId=01068801967, topicName=获得性耐药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sun Jan 24 15:28:00 CST 2016, time=2016-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=62222, encodeId=55a16222296, content=学习了继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=143, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIuqOuvZLWMJ8yAVHKNPBSKWLKHx7ibIhutJv2OfnTK9MQH5jpicpw5EJTmD0M0q2wOG3CZO9wTxa9A/132, createdBy=75561684788, createdName=yilibaisha, createdTime=Sat Jan 30 14:57:00 CST 2016, time=2016-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=61326, encodeId=8d756132666, content=不错，赞一个, beContent=null, objectType=article, channel=null, level=null, likeNumber=137, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Wed Jan 27 20:10:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=61327, encodeId=619c6132ebe, content=这篇文章有一定深度, beContent=null, objectType=article, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Wed Jan 27 20:10:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=61328, encodeId=9bfe6132839, content=是一篇不错的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Wed Jan 27 20:10:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=61329, encodeId=c0ee613290e, content=非常实用, beContent=null, objectType=article, channel=null, level=null, likeNumber=164, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Wed Jan 27 20:10:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=61330, encodeId=9ad5613301f, content=值得进一步关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=171, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Wed Jan 27 20:10:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=61089, encodeId=bca16108981, content=文章有深度, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Wed Jan 27 18:34:00 CST 2016, time=2016-01-27, status=1, ipAttribution=)]
2016-01-27 doctording1

非常实用

164 0
[GetPortalCommentsPageByObjectIdResponse(id=2042566, encodeId=5a2f2042566a2, content=<a href='/topic/show?id=999c88014ea' target=_blank style='color:#2F92EE;'>#获得性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88014, encryptionId=999c88014ea, topicName=获得性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d4b7363, createdName=pandamao2010, createdTime=Fri May 20 06:28:00 CST 2016, time=2016-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1753126, encodeId=b4891e5312658, content=<a href='/topic/show?id=6a57e33772b' target=_blank style='color:#2F92EE;'>#研究发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73377, encryptionId=6a57e33772b, topicName=研究发现)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e1736602208, createdName=hanhaisha2020, createdTime=Sat Aug 20 04:28:00 CST 2016, time=2016-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1967062, encodeId=8701196e062a2, content=<a href='/topic/show?id=01068801967' target=_blank style='color:#2F92EE;'>#获得性耐药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88019, encryptionId=01068801967, topicName=获得性耐药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sun Jan 24 15:28:00 CST 2016, time=2016-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=62222, encodeId=55a16222296, content=学习了继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=143, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIuqOuvZLWMJ8yAVHKNPBSKWLKHx7ibIhutJv2OfnTK9MQH5jpicpw5EJTmD0M0q2wOG3CZO9wTxa9A/132, createdBy=75561684788, createdName=yilibaisha, createdTime=Sat Jan 30 14:57:00 CST 2016, time=2016-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=61326, encodeId=8d756132666, content=不错，赞一个, beContent=null, objectType=article, channel=null, level=null, likeNumber=137, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Wed Jan 27 20:10:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=61327, encodeId=619c6132ebe, content=这篇文章有一定深度, beContent=null, objectType=article, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Wed Jan 27 20:10:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=61328, encodeId=9bfe6132839, content=是一篇不错的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Wed Jan 27 20:10:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=61329, encodeId=c0ee613290e, content=非常实用, beContent=null, objectType=article, channel=null, level=null, likeNumber=164, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Wed Jan 27 20:10:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=61330, encodeId=9ad5613301f, content=值得进一步关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=171, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Wed Jan 27 20:10:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=61089, encodeId=bca16108981, content=文章有深度, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Wed Jan 27 18:34:00 CST 2016, time=2016-01-27, status=1, ipAttribution=)]
2016-01-27 doctording1

值得进一步关注

171 0
[GetPortalCommentsPageByObjectIdResponse(id=2042566, encodeId=5a2f2042566a2, content=<a href='/topic/show?id=999c88014ea' target=_blank style='color:#2F92EE;'>#获得性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88014, encryptionId=999c88014ea, topicName=获得性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d4b7363, createdName=pandamao2010, createdTime=Fri May 20 06:28:00 CST 2016, time=2016-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1753126, encodeId=b4891e5312658, content=<a href='/topic/show?id=6a57e33772b' target=_blank style='color:#2F92EE;'>#研究发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73377, encryptionId=6a57e33772b, topicName=研究发现)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e1736602208, createdName=hanhaisha2020, createdTime=Sat Aug 20 04:28:00 CST 2016, time=2016-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1967062, encodeId=8701196e062a2, content=<a href='/topic/show?id=01068801967' target=_blank style='color:#2F92EE;'>#获得性耐药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88019, encryptionId=01068801967, topicName=获得性耐药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sun Jan 24 15:28:00 CST 2016, time=2016-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=62222, encodeId=55a16222296, content=学习了继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=143, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIuqOuvZLWMJ8yAVHKNPBSKWLKHx7ibIhutJv2OfnTK9MQH5jpicpw5EJTmD0M0q2wOG3CZO9wTxa9A/132, createdBy=75561684788, createdName=yilibaisha, createdTime=Sat Jan 30 14:57:00 CST 2016, time=2016-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=61326, encodeId=8d756132666, content=不错，赞一个, beContent=null, objectType=article, channel=null, level=null, likeNumber=137, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Wed Jan 27 20:10:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=61327, encodeId=619c6132ebe, content=这篇文章有一定深度, beContent=null, objectType=article, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Wed Jan 27 20:10:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=61328, encodeId=9bfe6132839, content=是一篇不错的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Wed Jan 27 20:10:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=61329, encodeId=c0ee613290e, content=非常实用, beContent=null, objectType=article, channel=null, level=null, likeNumber=164, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Wed Jan 27 20:10:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=61330, encodeId=9ad5613301f, content=值得进一步关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=171, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Wed Jan 27 20:10:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=61089, encodeId=bca16108981, content=文章有深度, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Wed Jan 27 18:34:00 CST 2016, time=2016-01-27, status=1, ipAttribution=)]
2016-01-27 李继凯

文章有深度

118 0

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

肿瘤科

研究发现肿瘤微环境导致获得性耐药新机制

相关资讯

科室

工具

服务